Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arcellx, Inc. (ACLX : NSDQ)

• Company Description    Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md. Number of Employees: 163

• Price / Volume Information    Yesterday's Closing Price: $76.19 Daily Weekly Monthly 20 Day Moving Average: 511,979 shares Shares Outstanding: 55.46 (millions) Market Capitalization: $4,225.42 (millions) Beta: 0.28 52 Week High: $107.37 52 Week Low: $47.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.03% 4.16% 12 Week 19.38% 8.44% Year To Date -0.65% -9.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 800 BRIDGE PARKWAY - REDWOOD CITY,CA 94065 USA ph: 240-327-0630 fax: - ir@arcellx.com http://www.arcellx.com

• General Corporate Information    Officers Rami Elghandour - Chief Executive Officer and Chairman Michelle Gilson - Chief Financial Officer Olivia Ware - Director Kavita Patel - Director Derek Yoon - Director Peer Information Arcellx, Inc. (CORR.) Arcellx, Inc. (RSPI) Arcellx, Inc. (CGXP) Arcellx, Inc. (BGEN) Arcellx, Inc. (GTBP) Arcellx, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03940C100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 55.46 Most Recent Split Date: (:1) Beta: 0.28 Market Capitalization: $4,225.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.91 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.70 Price/Cash Flow: - Price / Sales: 74.16 EPS Growth vs. Year Ago Period: -84.31% vs. Previous Quarter: 16.81% Sales Growth vs. Year Ago Period: -72.41% vs. Previous Quarter: -7.07% ROE 06/30/25 - -43.04 03/31/25 - -35.27 12/31/24 - -22.35 ROA 06/30/25 - -27.41 03/31/25 - -22.73 12/31/24 - -14.36 Current Ratio 06/30/25 - 3.81 03/31/25 - 4.93 12/31/24 - 4.78 Quick Ratio 06/30/25 - 3.81 03/31/25 - 4.93 12/31/24 - 4.78 Operating Margin 06/30/25 - -329.93 03/31/25 - -211.46 12/31/24 - -99.46 Net Margin 06/30/25 - -329.93 03/31/25 - -211.46 12/31/24 - -99.46 Pre-Tax Margin 06/30/25 - -326.84 03/31/25 - -208.77 12/31/24 - -97.54 Book Value 06/30/25 - 7.12 03/31/25 - 7.57 12/31/24 - 8.41 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©